Investigational drug · Phase 2
Dual-target CAR-NK cell product
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma.
Phase 2Last checked: Nov 20, 2026Latest source record: Jun 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
13
Any phase or sponsor naming "Dual-target CAR-NK cell product"
First trial start
2026
Feb 4, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Dual-target CAR-NK cell product", any sponsor or status.
- Phase 111
Conditions studied
As listed on its trial records.
- Epithelial Ovarian Cancer
- Primary Peritoneal Carcinoma
- Fallopian Tube Carcinoma
- Recurrent or Refractory Disease After Standard Therapies
Approved drugs for the same conditions: Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Dual-target CAR-NK cell product" as an intervention, largest first.
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)Not yet recruiting
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT07307053 · 600 participants (planned) · Start Jan 1, 2026 · Primary completion Jan 31, 2029
Drug: BL-B01D1; VSV injection and 18 more · For: Rare Malignant Neoplasm; Advanced Solid Tumors; Metastatic Solid Tumors
Sung-Soo ParkAcademic, hospital or other
NCT07051850 · 174 participants (planned) · Start Jul 14, 2025 · Primary completion Dec 31, 2025
Drug: Bispecific antibody; Antibody-Drug Conjugate and 4 more · For: Multiple Myeloma, Relapsed; Multiple Myeloma (MM)
Sites: Seocho, South Korea
- Immunotherapy in LymphomaRecruiting
Sung-Soo ParkAcademic, hospital or other
NCT06796517 · 72 participants (planned) · Start Jun 26, 2024 · Primary completion Dec 2025
Drug: CAR-T Therapy; Bispecific antibody and 4 more · For: Relapsed/refractory High Grade B Cell Lymphoma; High Grade B-cell Lymphoma; Diffuse Large B Cell Lymphoma Relapsed and 2 more
Sites: Seoul, South Korea · 2 sites in all
- PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid TumorsRecruiting
Beijing BiotechIndustry
NCT07510828 · 60 participants (planned) · Start Mar 2, 2026 · Primary completion Mar 14, 2027
Drug: EB-PT-CAR-NK-S; EB-PT-CAR-NK-D and 2 more · For: Advanced or Metastatic Solid Tumors
Sites: Shenzhen, China
Beijing BiotechIndustry
NCT07744256 · 60 participants (planned) · Start Mar 2, 2026 · Primary completion Feb 14, 2027
Drug: EB-DART-NK01; Lymphodepleting chemotherapy · For: Small Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC; Extensive-stage SCLC
Sites: Shenzhen, China
Beijing BiotechIndustry
NCT07480928 · 42 participants (planned) · Start Feb 2, 2026 · Primary completion Feb 14, 2027
Drug: EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1); EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1) and 1 more · For: Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease
Sites: Shenzhen, China
Beijing BiotechIndustry
NCT07622940 · 36 participants (planned) · Start Mar 2, 2026 · Primary completion Mar 14, 2027
Drug: EBNK-1822H2 dual-target CLDN18.2/HER2 CAR-NK cells; Fludarabine and 1 more · For: Recurrent or Metastatic Esophageal Adenocarcinoma; Biomarker-selected CLDN18.2-positive and/or HER2-positive Disease
Sites: Shenzhen, China
- Dual-Targeting CAR-NK Cell Therapy for Recurrent/Progressive Glioblastoma and High-Grade GliomaRecruiting
Beijing BiotechIndustry
NCT07480941 · 36 participants (planned) · Start Feb 2, 2026 · Primary completion Feb 18, 2027
Drug: Dual-target CAR-NK cells; Cyclophosphamide and 1 more · For: Glioblastoma; High-grade Glioma; Malignant Glioma and 2 more
Sites: Shenzhen, China
Beijing BiotechIndustry
NCT07480954 · 36 participants (planned) · Start Feb 4, 2026 · Primary completion Feb 17, 2027
Drug: Dual-target CAR-NK cell product; Lymphodepleting chemotherapy · For: Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Carcinoma and 1 more
Sites: Shenzhen, China
Beijing BiotechIndustry
NCT07510815 · 36 participants (planned) · Start Mar 2, 2026 · Primary completion Mar 14, 2027
Drug: EB-MF-CAR-NK-01; Fludarabine and 1 more · For: Malignant Pleural Mesotheliomas
Sites: Shenzhen, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Epithelial Ovarian Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- AZD5335Torvutatug samrotecan, Torvu-samPhase 34 trials
AstraZeneca · Epithelial Ovarian Cancer, Ovarian Cancer, Lung Adenocarcinoma
- IMNN-001IL-12 Plasmid with PEG-PEI-Cholesterol Lipopolymer, GEN-1Phase 33 trials
Imunon · Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer
- RC88The RC88Phase 23 trials
RemeGen Co., Ltd. · Solid Tumor, Advanced Solid Tumours, Primary Peritoneal Cancer
- AVZO-021Phase 22 trials
Avenzo Therapeutics, Inc. · HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, Advanced Solid Tumor
- CBX-12Phase 21 trial
Cybrexa Therapeutics · Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma
- ETX-19477Phase 21 trial
858 Therapeutics, Inc. · Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer
- KAND567FractalkinePhase 21 trial
Novakand Pharma AB · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.